Penn State's Nittany Angels backs eye-care startup in first $500K deal

What's the deal? Nittany Angels, an investment network connecting Penn State alumni with early-stage companies, has committed $500,000 to BioLatticeDealroom has a profile for this one. Try Dealroom → Ophthalmics in its first-ever investment. The seed round also drew biosei labs and George Perry. BioLattice, led by Penn State alumna Linda Alunkal, is developing an engineered corneal implant as an alternative to donor tissue.

What's the endgame? BioLattice's implant, called CorneaClear, aims to address corneal disease, a major cause of vision loss worldwide where access to donor tissue is limited. The company says its technology avoids the rejection risk and lifetime immunosuppressant use tied to donor corneas, and costs less than a transplant.

Why now? For the network, the deal is a first test of its model. Nittany Angels launched with a $1.5 million philanthropic gift to provide early-stage capital for Penn State-linked startups.

What's the endgame for Nittany Angels? The group evaluates companies on technology, market opportunity, leadership, and the path toward clinical, regulatory, and commercial milestones. "BioLattice is a strong first investment on every front," said program director Kunigunda Szentes Smyth, citing "a purpose-driven team with remarkable technology and a soaring market need."

What could go wrong? At $500,000, the check is modest and the company remains at seed stage. Its clinical progress and ability to secure follow-on funding will matter more than the announcement alone.

The signal: The round sits near the middle of the funding spectrum, in the 20th percentile by size. Yet investor appetite for unmet eye-care needs is real: in July, Claris Bio raised a $118 million Series B to push a corneal-disease drug toward pivotal trials. BioLattice is a far earlier bet — but one that will show whether university research can become an investable company.

Read more: psu.edu

Image credit: BioLattice